<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Human T-lymphotropic virus type I (HTLV-I) is the causative agent in adult T-cell <z:hpo ids='HP_0001909'>leukemia</z:hpo> and HTLV-I associated <z:hpo ids='HP_0002196'>myelopathy</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Some other diseases such as <z:hpo ids='HP_0000554'>uveitis</z:hpo>, <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0100646'>thyroiditis</z:hpo>, <z:e sem="disease" ids="C1527336" disease_type="Disease or Syndrome" abbrv="">Sj√∂gren</z:e> syndrome, <z:hpo ids='HP_0001369'>arthritis</z:hpo>, <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> may be also associated with HTLV-I </plain></SENT>
<SENT sid="2" pm="."><plain>Several case reports have suggested the possible combination of <z:hpo ids='HP_0001973'>idiopathic thrombocytopenic purpura</z:hpo> (<z:chebi fb="0" ids="16039">ITP</z:chebi>) and <z:e sem="disease" ids="C0020097" disease_type="Disease or Syndrome" abbrv="">HTLV-I infection</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>In these studies and from our current report, we found 17 patients (22.1%) with <z:e sem="disease" ids="C0020097" disease_type="Disease or Syndrome" abbrv="">HTLV-I infection</z:e> among 77 ITP patients </plain></SENT>
<SENT sid="4" pm="."><plain>The prevalence of <z:e sem="disease" ids="C0020097" disease_type="Disease or Syndrome" abbrv="">HTLV-I infection</z:e> among <z:chebi fb="0" ids="16039">ITP</z:chebi> patients was higher than that of healthy volunteers (5 approximately 10%) </plain></SENT>
<SENT sid="5" pm="."><plain>The <z:chebi fb="0" ids="16039">ITP</z:chebi> patients with <z:e sem="disease" ids="C0020097" disease_type="Disease or Syndrome" abbrv="">HTLV-I infection</z:e> were older than the patients without <z:e sem="disease" ids="C0020097" disease_type="Disease or Syndrome" abbrv="">HTLV-I infection</z:e>, and the <z:chebi fb="0" ids="16039">ITP</z:chebi> patients with <z:e sem="disease" ids="C0020097" disease_type="Disease or Syndrome" abbrv="">HTLV-I infection</z:e> had poor response to <z:chebi fb="2" ids="8378">prednisolone</z:chebi> therapy </plain></SENT>
<SENT sid="6" pm="."><plain>Among 17 ITP patients with <z:e sem="disease" ids="C0020097" disease_type="Disease or Syndrome" abbrv="">HTLV-I infection</z:e>, 9 patients received <z:chebi fb="2" ids="8378">prednisolone</z:chebi> therapy </plain></SENT>
<SENT sid="7" pm="."><plain>Although most patients had transient increase of platelet counts, only two of them had partial responses (PR) at the last observation date </plain></SENT>
<SENT sid="8" pm="."><plain>Five patients underwent splenectomy, and four of them had complete responses (CR) and the remaining patient had a (PR) </plain></SENT>
<SENT sid="9" pm="."><plain>Four patients received eradication of Helicobactor pylori (H. pylori) <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e>, and <z:hpo ids='HP_0000001'>all</z:hpo> patients had CRs </plain></SENT>
<SENT sid="10" pm="."><plain>Therefore, the <z:chebi fb="0" ids="16039">ITP</z:chebi> patients with <z:e sem="disease" ids="C0020097" disease_type="Disease or Syndrome" abbrv="">HTLV-I infection</z:e> should receive eradication therapy in the case of H. pylori <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> as the first step of therapy and the splenectomy should be considered, if there is no response to conventional therapy </plain></SENT>
<SENT sid="11" pm="."><plain>Human <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> virus (HIV) causes <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> in 10% of patients with active <z:e sem="disease" ids="C0019693" disease_type="Disease or Syndrome" abbrv="">HIV disease</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>The etiologies of HIV <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> are considered as follows, the escalated destruction of platelets by the immune system, damage to megakaryocytes by <z:e sem="disease" ids="C0019693" disease_type="Disease or Syndrome" abbrv="">HIV infection</z:e> and the inhibition of thrombopoiesis by some anti-<z:mp ids='MP_0001799'>viral</z:mp> drugs </plain></SENT>
<SENT sid="13" pm="."><plain>In the case of <z:chebi fb="0" ids="16039">ITP</z:chebi> patients with <z:e sem="disease" ids="C0020097" disease_type="Disease or Syndrome" abbrv="">HTLV-I infection</z:e>, the main etiology may be the increased destruction of platelets by immune system </plain></SENT>
<SENT sid="14" pm="."><plain>The proviral load and the integration pattern of HTLV-I should be examined to clarify the stage of <z:e sem="disease" ids="C0020097" disease_type="Disease or Syndrome" abbrv="">HTLV-I infection</z:e> </plain></SENT>
<SENT sid="15" pm="."><plain>The possibility of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> of the megakaryocytes by HTLV-I should be also examined for etiological approach </plain></SENT>
</text></document>